GT Biopharma Inc.

Last updated September 27, 2026

Favorite this organization

Organization details

Legal name: GT Biopharma Inc.
Former names: Oxis International Inc
Ownership: Public
Status: Active
Sector (GICS): Health Care
SIC code: 2834 — Pharmaceutical Preparations
Jurisdiction of incorporation: Delaware
Headquarters city: SAN Francisco
Headquarters state / province: California
Headquarters country: United States
Fiscal year end: December
Ticker symbol: GTBP
Primary stock exchange: Nasdaq

Identifiers

SEC CIK: 0000109657
EIN: 94-1620407

Board of directors

Follow this board

Andrew J. Ritter · Director
Since 2025
Bruce Wendel · Director
Since 2023
Charles J. Casamento · Director
Since 2023
David C. Mun-Gavin · Director
Since 2025
Hilary Kramer · Director
Since 2025
Michael Martin Breen · Director · CEO and Director
Since 2023
Rajesh C. Shrotriya M.D. · Director
Since 2023

Chief executives

Michael Martin Breen · Exec Chairman and Interim CEO Interim

Dates unknown

Director election results

Annual meeting of August 14, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Board connections

3 of this board's directors also sit on 6 other boards. 4 are in the same sector.

Shared director Other board Same sector

Eton Pharmaceuticals Inc. Same sector
via Charles J. Casamento
GridAI Technologies Corp.
via Charles J. Casamento
ImmunityBio Inc. Same sector
via Bruce Wendel
PDS Biotechnology Corporation Same sector
via Bruce Wendel
Prairie Operating Co.
via Michael Martin Breen
Relmada Therapeutics Inc. Same sector
via Charles J. Casamento

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months: $0; 0 purchases by 0 insiders
Sold, last 12 months: $0; 0 sales by 0 insiders

Date	Insider	Transaction	Shares	Price	Value
Aug 11, 2023	Michael Martin Breen Director, Officer (Executive Chairman/Interim CEO)	Grant or award	+200,000	$0.29	$58,000
Aug 11, 2023	Ohri Manu Officer (CFO & Secretary)	Grant or award	+200,000	$0.29	$58,000
Aug 11, 2023	Ohri Manu Officer (CFO & Secretary)	Other	−200,000	$0.29	$58,000
Aug 11, 2023	Ohri Manu Officer (CFO & Secretary)	Other	+200,000	$0.29	$58,000
Apr 11, 2023	Michael Martin Breen Director, Officer (Executive Chairman/Interim CEO)	Open-market purchase	+50,000	$0.50	$25,000
Apr 6, 2023	Ohri Manu Officer (CFO & Secretary)	Open-market purchase	+50,000	$0.50	$25,000

Peers

Compare boards

Organizations in the same sector, closest in location and size first.

3M Company NYSE: MMM · ST Paul, United States Organization ABVC BioPharma Inc. Nasdaq: ABVC · Fremont, United States Organization ACADIA Pharmaceuticals Inc. Nasdaq: ACAD · SAN Diego, United States Organization ADMA Biologics Inc Nasdaq: ADMA · Ramsey, United States Organization

Questions about GT Biopharma Inc.

Who is the CEO of GT Biopharma Inc.?

Michael Martin Breen is GT Biopharma Inc.'s Exec Chairman and Interim CEO.

How many directors are on GT Biopharma Inc.'s board?

GT Biopharma Inc.'s board has 7 directors: Andrew J. Ritter, Bruce Wendel, Charles J. Casamento, David C. Mun-Gavin, Hilary Kramer, Michael Martin Breen and Rajesh C. Shrotriya M.D.

How is GT Biopharma Inc. connected to…? → Spot something wrong? Report a correction

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="gt-biopharma-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

No reviews yet. Be the first to write one.